LAMEA Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Non-Melanoma and Melanoma), By Test Type (Skin Biopsy, Imaging Tests, Dermatoscopy, Lymph Node Biopsy, and Others), By End-use, By Country and Growth Forecast, 2024 - 2031

The Latin America, Middle East and Africa Skin Cancer Diagnostics Market is projected to witness market growth of 7.6% CAGR during the forecast period (2024-2031).

The Brazil market dominated the LAMEA Skin Cancer Diagnostics Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $267.1 million by 2031. The Argentina market is showcasing a CAGR of 8.3% during (2024 - 2031). Additionally, The UAE market is registering a CAGR of 6.6% during (2024 - 2031).



The skin cancer diagnostics market has become a critical segment of the broader healthcare industry as a result of the increasing prevalence of skin cancer. As one of the most common forms of cancer, skin cancer includes various types, primarily categorized into melanoma and non-melanoma skin cancers (NMSC).

Additionally, the increasing incidence of these cancers has driven significant advancements in diagnostic technologies and methods, transforming the landscape of dermatological care. This market is influenced by many factors, ranging from demographic shifts and lifestyle changes to technological innovations and healthcare policies.

In numerous LAMEA countries, the prevalence of cutaneous cancer is increasing. This is attributed to increased sun exposure due to outdoor lifestyles and occupations and a lack of public awareness about skin cancer prevention. This rise in cases fuels the need for accessible and efficient diagnostic tools. In Brazil, the rising incidence of skin cancer is closely linked to increasing awareness and the implementation of extensive screening programs. According to the World Cancer Research Fund, Brazil reported 9,676 new cases of skin cancer in 2022.

List of Key Companies Profiled

• Castle Biosciences, Inc.
• Bausch Health Companies, Inc. (DermTech, Inc.)
• Canfield Scientific, Inc.
• DermaSensor, Inc.
• F.Hoffmann-La Roche Ltd.
• NeoGenomics, Inc.
• Quest Diagnostics Incorporated.
• Digital Diagnostics, Inc. (3Derm Systems, Inc.)
• FotoFinder Systems GmbH
• Veriskin Inc

Market Report Segmentation

By Type

• Non-Melanoma
• Melanoma

By Test Type

• Skin Biopsy
• Imaging Tests
• Dermatoscopy
• Lymph Node Biopsy
• Others

By End-use

• Hospital & Clinics
• Laboratories
• Others

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA